The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity
Open accessAbstract
The Endothelial Activation and Stress Index (EASIX) score, defined as [(creatinine × lactate dehydrogenase [LDH])/platelets], is a marker of endothelial activation that has been validated in the allogeneic hematopoietic stem cell transplant setting. Endothelial activation is one of the mechanisms driving immune-mediated toxicities in patients treated with chimeric antigen receptor-T (CAR-T)-cell therapy. This study’s objective was to evaluate the association between EASIX and other laboratory parameters collected before lymphodepletion and the subsequent onset of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) those patients. Toxicity data were collected prospectively on 171 patients treated with axicabtagene ciloleucel (axi-cel) for large B-cell lymphoma (LBCL). CRS grades 2 to 4 were diagnosed in 81 (47%) patients and ICANS grades 2 to 4 in 84 (49%). EASIX combined with ferritin (EASIX-F) identified 3 risk groups with CRS grades 2 to 4 cumulative incidence of 74% (hazards ratio [HR], 4.8; 95% confidence interval [CI], 2.1-11; P < .001), 49% (HR, 2.3; 95% CI, 1.02-5; P = .04), and 23% (reference), respectively. EASIX combined with CRP and ferritin (EASIX-FC) identified 3 risk groups with an ICANS grade 2 to 4 cumulative incidence of 74% (HR, 3.6; 95% CI, 1.9-6.9; P < .001), 51% (HR, 2.1; 95% CI, 1.1-3.9; P = .025), and 29% (reference). Our results indicate that common laboratory parameters before lymphodepletion correlate with CAR-T–related toxicities and can help support clinical decisions, such as preemptive toxicity management, hospitalization length, and proper setting for CAR-T administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438 · cited 1×
“Toxicity was prospectively graded according to the CARTOX(15) and ASTCT consensus grading systems,(16) and treatment was administered according to the CARTOX treatment protocol.(15) Grades 2 to 4 CRS and ICANS were selected, with the intention of having an adequate number of events to allow for statistical power and o…”
MethodSelf-citationAbramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31366-0 · Cited by 2,430 · cited 10×
“, P 5 .01) ICANS.”
BackgroundInfluentialSelf-citationNorelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0036-4 · Cited by 1,406 · cited 2×
“although blocking of IL-6 with tocilizumab ameliorated CRS, the mice had delayed neurotoxicity, accompanied by meningeal macrophage infiltration.(20) In a study of 133 patients with B-cell malignancies who received a CD19 CAR T-cell product, high-grade ICANS was associated with low blood pressure, hypoxia, low serum p…”
BackgroundGust, J., Hay, K. A., Hanafi, L.-A., Li, D., Myerson, D., Gonzalez-Cuyar, L. F., Yeung, C., Liles, W. C., Wurfel, M., Lopez, J. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0698 · Cited by 1,400 · cited 2×
“In a study of 133 patients with B-cell malignancies who received a CD19 CAR T-cell product, high-grade ICANS was associated with low blood pressure, hypoxia, low serum protein, and albumin levels, and weight gain, suggesting a systemic capillary leak syndrome, potentially related to endothelial dysfunction.(9) In the…”
BackgroundCAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0041-7 · Cited by 1,272 · cited 1×
“In preclinical models, the development of CRS has been shown to be secondary to both CAR T-cell expansion and to subsequent activation of the immune microenvironment, leading to a cytokine storm, including peak levels of in IL-1, IL-6, and other proinflammatory molecules.(19,20) Of interest, in patient-derived samples…”
BackgroundHay, K. A., Hanafi, L.-A., Li, D., Gust, J., Liles, W. C., Wurfel, M. M., López, J. A., Chen, J., Chung, D., Harju-Baker, S., et al. (2017) · Blood · doi:10.1182/blood-2017-06-793141 · Cited by 1,156 · cited 7×
“Upon recognition of their target antigen, CAR T cells are activated and expand through a cascade of immune stimuli, not limited to the CAR T cells themselves.(4) Interferon-g (IFN-g) secreted by CAR T cells leads to stimulation of macrophages, which may in turn cause vascular endothelial activation and coagulopathy, t…”
BackgroundMethodInfluentialNastoupil, L. J., Jain, M. D., Feng, L., Spiegel, J. Y., Ghobadi, A., Lin, Y., Dahiya, S., Lunning, M., Lekakis, L., Reagan, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02104 · Cited by 801
Self-citationDean, E. A., Mhaskar, R. S., Lu, H., Mousa, M. S., Krivenko, G. S., Lazaryan, A., Bachmeier, C. A., Chavez, J. C., Nishihori, T., Davila, M. L., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001900 · Cited by 256
Cited by
Current understanding and management of CAR T cell-associated toxicities
Brudno, J. N., & Kochenderfer, J. N. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00903-0 · Cited by 305
Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma
Caimi, P. F., Pacheco Sanchez, G., Sharma, A., Otegbeye, F., Ahmed, N., Rojas, P., Patel, S., Kleinsorge Block, S., Schiavone, J., Zamborsky, K., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.745320 · Cited by 121
Metadata
- Authors
- Greenbaum, U., Strati, P., Saliba, R. M., Torres, J., Rondon, G., Nieto, Y., Hosing, C., Srour, S. A., Westin, J., Fayad, L. E., Lee, H. J., Iyer, S. P., Nair, R., Nastoupil, L. J., Parmar, S., Rodriguez, M. A., Samaniego, F., Steiner, R. E., Wang, M., Pinnix, C. C., Flowers, C. R., Tummala, S., Ramdial, J. L., Yalniz, F. F., Hawkins, M., Rezvani, K., Champlin, R. E., Shpall, E. J., Neelapu, S. S., Kebriaei, P., & Ahmed, S.
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2021-07-15
- Volume
- 5
- Issue
- 14
- Pages
- 2799-2806
- ISSN
- 2473-9529 (ISSN-L)
- 2473-9537
- OpenAlex
- W3181838868
- Cited by
- 158
- References
- 8
- FWCI
- 6.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity. https://app.cochat.ai/papers/10.1182/bloodadvances.2021004575
- The paper
- Greenbaum, U., Strati, P., Saliba, R. M., Torres, J., Rondon, G., Nieto, Y., Hosing, C., Srour, S. A., Westin, J., Fayad, L. E., Lee, H. J., Iyer, S. P., Nair, R., Nastoupil, L. J., Parmar, S., Rodriguez, M. A., Samaniego, F., Steiner, R. E., Wang, M., . . . Ahmed, S. (2021). CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity. Blood Advances. https://doi.org/10.1182/bloodadvances.2021004575
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.